Caspase Recruitment Domain Containing Protein 9 Suppresses Non-small Cell Lung Cancer Proliferation and Invasion via Inhibiting MAPK/p38 Pathway

被引:9
作者
Pan, Linyue [1 ]
Tan, Yuting [1 ]
Wang, Bin [2 ]
Qiu, Wenjia [1 ]
Yin, Yulei [3 ]
Ge, Haiyan [1 ]
Zhu, Huili [1 ]
机构
[1] Fudan Univ, Affiliated Huadong Hosp, Dept Resp Med, 221 West Yanan Rd, Shanghai 200040, Peoples R China
[2] Fudan Univ, Affiliated Huadong Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[3] Fudan Univ, Affiliated Huadong Hosp, Dept Pathol, Shanghai, Peoples R China
来源
CANCER RESEARCH AND TREATMENT | 2020年 / 52卷 / 03期
基金
中国国家自然科学基金;
关键词
CARD9; Non-small cell lung cancer; Prognosis; Targeted therapy; CARD9; ADAPTER; ACTIVATION; RECOGNITION; RESPONSES; DECTIN-2; COLITIS; TARGET;
D O I
10.4143/crt.2019.606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Caspase recruitment domain containing protein 9 (CARD9) has been demonstrated to be a pro-tumor factor in various cancers. However, our previous study found a significant decrease of CARD9 in malignant pleural effusion compared with benign pleural effusion. So we investigated the role of CARD9 in non-small cell lung cancer (NSCLC) and its working mechanism. Materials and Methods Immunohistochemistry, western blot, and quantitative real-time polymerase chain reaction were used to detect the expression of CARD9 in specimens of NSCLC patients. The Cancer Genome Atlas (TCGA) database was also used to analyze the expression of CARD9 in NSCLC and its predicting value for prognosis. Immunofluorescence was used for CARD9 cellular location. Cell growth assay, clonal formation assay, wound healing assay, matrigel invasion assay, and flow cytometry were used to test cell proliferation, migration, invasion, apoptosis, and cycle progression of NSCLC cells with CARD9 knockdown or CARD9 overexpression. Co-immunoprecipitation was used to identify the interaction between CARD9 and B-cell lymphoma 10 (BCL10). SB203580 was used to inhibit p38 activation. Results CARD9 was decreased in NSCLC tissues compared with normal tissues; low CARD9 expression was associated with poor survival. CARD9 was expressed both in tumor cells and macrophages. Downregulation of CARD9 in NSCLC cells enhanced the abilities of proliferation, invasion, and migration via activated mitogen-activated protein kinases (MAPK)/p38 signaling, while overexpression of CARD9 presented antitumor effects. BCL10 was identified to interact with CARD9. Conclusion We demonstrate that CARD9 is an independent prognostic factor in NSCLC patients and inhibits proliferation, migration, and invasion by suppressing MAPK/p38 pathway in NSCLC cells.
引用
收藏
页码:867 / 885
页数:19
相关论文
共 27 条
  • [1] American Cancer Society, 2019, Cancer Treatment Survivorship Facts Figures 2019-2021, DOI DOI 10.1080/15398285.2012.701177
  • [2] Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma
    An, Jiabin
    Liu, Huiren
    Magyar, Clara E.
    Guo, Yanchuan
    Veena, Mysore S.
    Srivatsan, Eri S.
    Huang, Jiaoti
    Rettig, Matthew B.
    [J]. CANCER RESEARCH, 2013, 73 (04) : 1374 - 1385
  • [3] Card9-dependent IL-β regulates IL-22 production from group 3 innate lymphoid cells and promotes colitis-associated cancer
    Bergmann, Hanna
    Roth, Susanne
    Pechloff, Konstanze
    Kiss, Elina A.
    Kuhn, Sabine
    Heikenwaelder, Mathias
    Diefenbach, Andreas
    Greten, Florian R.
    Ruland, Juergen
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 47 (08) : 1342 - 1353
  • [4] Tumor-Associated Macrophages Derived TGF-β-Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway
    Cai, Jianhui
    Xia, Limin
    Li, Jinlei
    Ni, Shichang
    Song, Huayu
    Wu, Xiangbin
    [J]. CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 252 - 266
  • [5] Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation
    Cao, Zhifang
    Conway, Kara L.
    Heath, Robert J.
    Rush, Jason S.
    Leshchiner, Elizaveta S.
    Ramirez-Ortiz, Zaida G.
    Nedelsky, Natalia B.
    Huang, Hailiang
    Ng, Aylwin
    Gardet, Agnes
    Cheng, Shih-Chin
    Shamji, Alykhan F.
    Rioux, John D.
    Wijmenga, Cisca
    Netea, Mihai G.
    Means, Terry K.
    Daly, Mark J.
    Xavier, Ramnik J.
    [J]. IMMUNITY, 2015, 43 (04) : 715 - 726
  • [6] p38β, A Novel Regulatory Target of Pokemon in Hepatic Cells
    Chen, Zhe
    Liu, Feng
    Zhang, Nannan
    Cao, Deliang
    Liu, Min
    Tan, Ying
    Jiang, Yuyang
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (07): : 13511 - 13524
  • [7] Card9 controls Dectin-1-induced T-cell cytotoxicity and tumor growth in mice
    Haas, Tobias
    Heidegger, Simon
    Wintges, Alexander
    Bscheider, Michael
    Bek, Sarah
    Fischer, Julius C.
    Eisenkolb, Gabriel
    Schmickl, Martina
    Spoerl, Silvia
    Peschel, Christian
    Poeck, Hendrik
    Ruland, Juergen
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 47 (05) : 872 - 879
  • [8] The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors
    Hara, Hiromitsu
    Ishihara, Chitose
    Takeuchi, Arata
    Imanishi, Takayuki
    Xue, Liquan
    Morris, Stephan W.
    Inui, Masanori
    Takai, Toshiyuki
    Shibuya, Akira
    Saijo, Shinobu
    Iwakura, Yoichiro
    Ohno, Naohito
    Koseki, Haruhiko
    Yoshida, Hiroki
    Penninger, Josef M.
    Saito, Takashi
    [J]. NATURE IMMUNOLOGY, 2007, 8 (06) : 619 - 629
  • [9] The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens
    Hsu, Yen-Michael S.
    Zhang, Yongliang
    You, Yun
    Wang, Donghai
    Li, Hongxiu
    Duramad, Omar
    Qin, Xiao-Feng
    Dong, Chen
    Lin, Xin
    [J]. NATURE IMMUNOLOGY, 2007, 8 (02) : 198 - 205
  • [10] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20107, 10.3322/caac.20115, 10.3322/caac.21492]